On May 4, the U.S. Food and Drug Administration (FDA) approved the FoundationOne®Liquid CDx to be used as a companion diagnostic for mobocertinib, which is currently FDA-approved for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.
For more information, read the Foundation Medicine announcement.
Posted 5/4/2023
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
